Edoxaban

Summary

Edoxaban (CHEMBL1269025) is an approved small-molecule anticoagulant (ATC B01AF03) targeting F10; indicated across 15 conditions including thrombotic disease and venous thromboembolism.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B01AF03
• Targets: 1 (F10)
• Indications: 15 conditions
• Clinical trials: 91
• Chemistry: 548.1 Da · C24H30ClN7O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1269025
Name	Edoxaban
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	10280735
ChEBI	CHEBI:85973
ATC	B01AF03
Molecular formula	C24H30ClN7O4S
Molecular weight	548.1
InChIKey	HGVDHZBSSITLCT-JLJPHGGASA-N

SMILES: CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C

IUPAC name: N’-(5-chloro-2-pyridinyl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide

ChEBI definition: A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism.

Pharmacological roles (ChEBI): anticoagulant, EC 3.4.21.6 (coagulation factor Xa) inhibitor, platelet aggregation inhibitor.

Also known as: DU-176, Edoxaban, EDOXABAN

Parent form; salt/anhydrous children: CHEMBL2105682, CHEMBL3542264

Patent coverage: 1,001 distinct patent families (2,356 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
F10	coagulation factor X	Inhibition	9.25	0%	P00742

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Prothrombin, Coagulation factor X, Prothrombinase complex.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
F10	9.25	Ki	0.56	nM	CHEMBL_ACT_25028376
F10	9.25	Ki	0.56	nM	CHEMBL_ACT_25708412
F10	9.25	Ki	0.56	nM	CHEMBL_ACT_26024764
F10	9.25	Ki	0.56	nM	CHEMBL_ACT_3515088
F10	8.53	Ki	2.98	nM	CHEMBL_ACT_25708408
F10	8.47	IC50	3.4	nM	CHEMBL_ACT_18733028
F10	8.47	IC50	3.4	nM	CHEMBL_ACT_19252398
F2	5.22	Ki	6000	nM	CHEMBL_ACT_26024765

Target pathways

Aggregated over 1 target gene(s): F10.

Top Reactome pathways

12 total, by targets touching each:

Pathway	Targets	Genes
R-HSA-140834	1	F10
R-HSA-140837	1	F10
R-HSA-140875	1	F10
Gamma-carboxylation of protein precursors	1	F10
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus	1	F10
Removal of aminoterminal propeptides from gamma-carboxylated proteins	1	F10
Defective factor IX causes thrombophilia	1	F10
Defective cofactor function of FVIIIa variant	1	F10
Defective F9 variant does not activate FX	1	F10
Initiation of coagulation cascade	1	F10
Regulation of clotting cascade	1	F10
Amplification and propagation of coagulation cascade	1	F10

Dominant GO biological processes

GO term	Targets
proteolysis	1
blood coagulation	1
positive regulation of cell migration	1
positive regulation of TOR signaling	1
hemostasis	1

Indications & clinical

Indications

15 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	4	MONDO:0000831	HP:0004419
venous thromboembolism	3	MONDO:0005399	EFO:0004286
atrial fibrillation	3	MONDO:0004981	EFO:0000275
heart disorder	3	MONDO:0005267	EFO:0003777
stroke disorder	3	MONDO:0005098	EFO:0000712
aortic valve stenosis	3	MONDO:0042981	EFO:0000266
severe acute respiratory syndrome	3	MONDO:0005091	EFO:0000694
peripheral arterial disease	2	MONDO:0005386	EFO:0004265
blood coagulation disease	2	MONDO:0001531	EFO:0009314
coronary artery disorder	2	MONDO:0005010	EFO:0001645
cirrhosis of liver	2	MONDO:0005155	EFO:0001422
acute myocardial infarction	2	MONDO:0004781	EFO:0008583

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 91.

Phase distribution

Phase	Trials
Not specified	37
PHASE3	21
PHASE4	16
PHASE2	9
PHASE2/PHASE3	4
PHASE1	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03129490	PHASE4	ACTIVE_NOT_RECRUITING	The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
NCT03129555	PHASE4	ACTIVE_NOT_RECRUITING	The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
NCT03950076	PHASE4	ACTIVE_NOT_RECRUITING	EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
NCT06650501	PHASE4	RECRUITING	Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
NCT02561897	PHASE4	TERMINATED	EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation
NCT02567461	PHASE4	COMPLETED	Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
NCT02935855	PHASE4	COMPLETED	ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
NCT03088072	PHASE4	UNKNOWN	A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure
NCT03463317	PHASE4	COMPLETED	Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
NCT03494530	PHASE4	COMPLETED	Lixiana Acute Stroke Evaluation Registry
NCT03666650	PHASE4	COMPLETED	NOAC Plasma Concentration and Blood Coagulation in Healthy Volunteers
NCT03718559	PHASE4	COMPLETED	Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease
NCT03840291	PHASE4	COMPLETED	Resolution of Thrombi in Left Atrial Appendage With Edoxaban
NCT03895502	PHASE4	COMPLETED	Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
NCT04072068	PHASE4	COMPLETED	Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy
NCT05320627	PHASE4	COMPLETED	Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation
NCT05035277	PHASE3	RECRUITING	AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
NCT06149533	PHASE3	NOT_YET_RECRUITING	Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
NCT06900725	PHASE2/PHASE3	NOT_YET_RECRUITING	Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke
NCT07454707	PHASE3	NOT_YET_RECRUITING	Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial
NCT00781391	PHASE3	COMPLETED	Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
NCT00986154	PHASE3	COMPLETED	Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
NCT01181102	PHASE3	COMPLETED	A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
NCT01181167	PHASE3	COMPLETED	A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT02072434	PHASE3	COMPLETED	Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
NCT02073682	PHASE3	COMPLETED	Cancer Venous Thromboembolism (VTE)
NCT02221102	PHASE2/PHASE3	UNKNOWN	Edoxaban for TIA and Acute Minor Stroke
NCT02618577	PHASE3	TERMINATED	Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
NCT02798471	PHASE3	COMPLETED	Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
NCT02866175	PHASE3	COMPLETED	Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
NCT02942576	PHASE3	COMPLETED	Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation
NCT03153150	PHASE3	COMPLETED	Start or STop Anticoagulants Randomised Trial (SoSTART)
NCT03244319	PHASE3	COMPLETED	Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)
NCT03395639	PHASE3	COMPLETED	Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
NCT03570281	PHASE2/PHASE3	UNKNOWN	Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)
NCT03961334	PHASE3	UNKNOWN	MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
NCT03996772	PHASE3	COMPLETED	PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
NCT04171726	PHASE3	UNKNOWN	Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation
NCT04516941	PHASE3	TERMINATED	CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19
NCT04730037	PHASE3	COMPLETED	Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 21 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

21 molecules share ≥1 primary target. Top 21 by shared-target count:

Molecule	Source	Status	Shared targets
APIXABAN	ChEMBL + PubChem	Phase 4 (approved)	F10
ARGATROBAN	ChEMBL	Phase 4 (approved)	F10
BETRIXABAN	ChEMBL	Phase 4 (approved)	F10
FONDAPARINUX	ChEMBL	Phase 4 (approved)	F10
MELAGATRAN	ChEMBL	Phase 4 (approved)	F10
PENTAMIDINE	ChEMBL	Phase 4 (approved)	F10
RIVAROXABAN	ChEMBL	Phase 4 (approved)	F10
DABIGATRAN	ChEMBL	Phase 3	F10
DAREXABAN	ChEMBL	Phase 3	F10
GABEXATE	ChEMBL	Phase 3	F10
NAFAMOSTAT	ChEMBL	Phase 3	F10
OTAMIXABAN	ChEMBL	Phase 3	F10
EFEGATRAN	ChEMBL	Phase 2	F10
ERIBAXABAN	ChEMBL	Phase 2	F10
FIDEXABAN	ChEMBL	Phase 2	F10
GW813893	ChEMBL	Phase 2	F10
LETAXABAN	ChEMBL	Phase 2	F10
LY-517717	ChEMBL	Phase 2	F10
RAZAXABAN	ChEMBL	Phase 2	F10
SEGATROXABAN	ChEMBL	Phase 2	F10
TANOGITRAN	ChEMBL	Phase 2	F10